Cash pulled forward: buyers are funding the company's next stage in advance, and the money keeps arriving
The model's full reasoning — Q3 2017 call → NOWe need answer only YES or NO. Need analyze transcript. Question: Does management describe that money or binding financial commitment is arriving at company ahead of work it will pay for, growing, and finances next stage? Need identify deposits, advances, prepayments, etc. In transcript: They mention "lack of contribution from advances of LaFerrari Aperta" in Q3 2017 vs prior year. Also "lack of contribution from advances of LaFerrari Aperta" as negative in cash flow. They mention "advances" in context of working capital. Also "FXX K EVO" maybe advances? They said "not going to impact Q4 in terms of advances." But is there a growing advance funding? They mention "robust waiting list" for Portofino, but not necessarily deposits. They mention "waiting list" but not advance payments. They mention "personalization programs" but not prepayments. They mention "advances of LaFerrari Aperta" as prior year contribution, now lacking. So not growing; it's declining. They mention "net change in working capital" due to trade payables etc. No mention of customers paying in advance growing. They mention "advances" only as lack of contribution. So answer NO. Need ensure no other. They mention "advances" in Q4? "lack of contribution from advances of LaFerrari Aperta" means in prior year they had advances, now not. So not growing. Also "FXX K EVO" not impact Q4 in terms of advances. So no. Thus answer NO.
| Ticker | Company | Call | Date | Call grade |
|---|---|---|---|---|
| PDS | Precision Drilling Corporation | Q1 2024 | 2024-04-25 | B |
| NBTX | Nanobiotix S.A. | Q2 2023 | 2023-09-27 | D |
| CRL | Charles River Laboratories International | Q2 2022 | 2022-08-03 | C |
| SYM | Symbotic Inc. | Q3 2022 | 2022-08-01 | B+ |
| VNRX | VolitionRx Limited | Q1 2022 | 2022-05-12 | F |
| FAT | FAT Brands Inc. | Q4 2021 | 2022-03-21 | F |
| GFS | GLOBALFOUNDRIES Inc. | Q3 2021 | 2021-11-30 | A |
| EEX | Emerald Holding, Inc. | Q2 2021 | 2021-08-01 | C+ |
| LIND | Lindblad Expeditions Holdings, Inc. | Q2 2017 | 2017-08-06 | C |
| PTC | PTC Inc. | Q3 2017 | 2017-07-19 | C+ |
| IONS | Ionis Pharmaceuticals, Inc. | Q1 2017 | 2017-05-09 | C |
SYM · Q3 2022 → YESThe question is about whether management describes that money or binding financial commitment is arriving at the company ahead of the work it will pay for, and they treat this as growing and financing...YES Management describes a "very significant cost float" from "strong deferred revenue on the balance sheet" that helps fund the company's growth strategy, along with improved payable terms. This ties directly to the $11.3 billion backlog and the ability to invest aggressively in scaling deployments, inventory, and operations ahead of full revenue recognition.
IONS · Q1 2017 → YESThe question is about whether management describes that money or binding financial commitment is arriving at the company ahead of the work it will pay for, and they treat this as growing and financing...YES Management describes exactly this pattern: Novartis delivered $175 million (including $75 million upfront plus $100 million equity at a premium) before the Phase IIb studies are conducted, and Bayer paid $75 million to advance IONIS-FXIRx and IONIS-FXI-LRx before full development work is complete 65-plus percent of which was already recognized in Q1.
LIND · Q2 2017 → YESThe question is about whether management describes that money or binding financial commitment is arriving at the company ahead of the work it will pay for, and if they treat this as growing and financ...YES The transcript shows management describing a clear pattern of advance bookings and forward reservations that are growing (nearly 40% year-to-date, up nearly 50% in July, highest booking day ever) and that directly de-risk and finance the next stage of growth.